Ticagrelor monotherapy after short DAPT in ACS: Time to turn theory into practice
Mattia Galli1, Sebastiano Sciarretta2
1Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
None:
Guidelines still recommend 12-month DAPT after acute coronary syndrome (ACS). This is possibly due to the insufficient power of most trials to detect hard ischemic endpoints, particularly in the subgroup of high ischemic-risk patients, such as those with ST-elevation ACS. Individual patient data meta-analyses play an important role in overcoming these limitations.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...


